Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGM707
- Development stage
- Phase 2
- Lead developer
- NGM Biopharmaceuticals
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NGM707 is a humanized, dual antagonist monoclonal antibody targeting the inhibitory immune checkpoint receptors ILT2 (immunoglobulin-like transcript 2) and ILT4. Developed by NGM Biopharmaceuticals, it is designed to improve patient immune responses to tumors by inhibiting both ILT2 and ILT4 receptors. Blockade of ILT4 reverses myeloid cell-mediated immune suppression, while blockade of ILT2 promotes NK and CD8+ T cell killing of tumor cells and activates macrophage phagocytosis. The dual blockade acts synergistically to reverse suppression in the tumor microenvironment, potentially enhancing anti-tumor immunity in patients with advanced solid tumors[1][2][6][7].
- Other names
- anti-ILT2/anti-ILT4 monoclonal antibody
02
Targets
LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)
Beyond the preview
Go deeper on NGM707.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGM707.